In tablet manufacturing, Yupi Zhike Powder is handled as a low-density botanical solid with variable particle geometry and a measurable sensitivity to over-compression. The initial unit operation is deagglomeration over a 0.180 mm stainless-steel screen, followed by pin milling if the oversize fraction exceeds 5% w/w. Bulk and tapped density are measured under USP <616>, and powder flow classification is performed under USP <1174>. A calculated Carr Index above 25 rules out direct compression for most compositions because hopper discharge becomes erratic and tablet weight variation increases on rotary presses operating above 30 rpm. Direct compression blends are prepared with microcrystalline cellulose at 30–60% w/w, lactose monohydrate at 20–40% w/w, crospovidone at 2–4% w/w, and magnesium stearate at 0.5–1.0% w/w. Tablet hardness is maintained at 50–70 N for film coating, friability is held below 0.8% using Ph. Eur. 2.9.7, and disintegration is evaluated in 0.1 N HCl at 37°C under USP <701> with a limit of 15 minutes.

When the unit dose requires more than 50 mg of the API per tablet, wet granulation is preferred because direct compression loses robustness and punch sticking becomes more frequent on extended runs. A high-shear granulator with an impeller speed of 300–600 rpm and a chopper speed of 1500–2500 rpm is charged with the dry components; purified water or a 5% povidone solution is sprayed at 1.0–2.0% w/w per minute until the wet mass reaches the target endpoint. Endpoint control is monitored by torque rise from the dry baseline; a total increase of 20–30 Nm typically corresponds to granules of 1–2 mm after hand squeeze. Drying is carried out in a fluid-bed dryer at an inlet air temperature of 60–70°C, with the product temperature maintained at 35–45°C and final loss on drying controlled at 2–4% under USP <731>. Dried granules are screened through a 0.8 mm sieve before compression. Published pilot data for comparable botanical powders indicate that tablet hardness can fall by 15–20% when granule moisture exceeds 5.0% at the press, and ejection force can rise by 25% when magnesium stearate is under-blended below the optimised lubrication time.

What limits sterile filtration of aqueous herbal extracts intended for injectable dosage?

The unprocessed veterinary-grade powder is not directly injectable. An injectable preparation can only be developed from the clarified aqueous or hydroalcoholic extract of the powder, and this route requires a deliberately staged filtration sequence. The extraction is chilled to 4°C for mucilage and polysaccharide precipitation, then clarified through a depth filter rated at 0.45 µm before terminal sterile filtration through a 0.22 µm polyethersulfone membrane. The filter train is sized with at least 1.5 m² of membrane area per 100 L batch because botanical polysaccharides progressively foul membranes and reduce flux. A pressure drop exceeding 2.5 bar before the full batch has passed signals that the extract was insufficiently clarified and that an additional depth-filtration step is required. Terminal sterilisation at 121°C for 15 minutes is acceptable only if marker assay, pH, and colour remain within the pre-approved stability envelope; otherwise aseptic processing must be used. The finished injectable must meet the sterility requirements of USP <71>, particulate matter limits of USP <788>, visible particulate requirements of USP <790>, pH control under USP <791>, and osmolality measurement under USP <785>. Bacterial endotoxin is tested under USP <85>; a common internal limit for botanical injectable APIs is below 0.5 EU/mg, with the finished-product limit calculated from the dose volume and body weight.

For hard-shell capsule filling, the API is pre-blended with lactose monohydrate or mannitol and a disintegrant. Powder rheology, not capsule shell size, is the dominant process variable. Tamping-pin fillers with dosing chamber diameters of 8–12 mm and filling speeds of 50–100 cycles per minute require a stable plug hardness between 2.5 and 5.0 N to avoid shell splitting and under-filling. Lubricant content above 1.0% w/w magnesium stearate delays dissolution because hydrophobic films form on botanical particles. Dissolution is tested under USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl; a provisional target of Q 80% at 60 minutes is applied unless the product dossier specifies a different acceptance limit. Capsule content uniformity is assessed under USP <905> with an acceptance value L1 ≤15.0.

Moisture exchange between the powder and capsule shell is controlled at the filling environment. Hypromellose shells are filled at 35–45% relative humidity to prevent brittleness, while gelatin shells are normally held at 40–50% relative humidity. Because the subject API is of botanical origin, its equilibrium moisture content can shift the internal moisture of the filled capsule during storage. Accelerated stability at 40°C and 75% RH for 6 months is the standard screening condition; dissolution, assay, and moisture are monitored at 0, 1, 2, 3, and 6 months. Batch-to-batch particle-size variation is controlled by sieve analysis after milling, with the mass fraction below 74 µm limited to 15–25% to reduce dust loss while preserving capsule fill weight. Published data for this exact botanical capsule formulation is limited; the manufacturer should generate bracketing data across shell suppliers where possible.

Wet granulation endpoint control in high-shear processing of coarse botanical APIs

When the API is formulated as granules for oral administration in feed or drinking water, the granulation step must produce a dust-controlled, freely dispensible intermediate rather than a compressed solid. High-shear wet granulation begins with dry mixing at an impeller speed of 300 rpm and a chopper speed of 1500 rpm. Purified water or a binding solution is sprayed at 1.0–2.0% w/w per minute. The endpoint is reached when the wet mass shows a torque rise of 20–30 Nm from baseline or when manual squeeze produces granules of 1–2 mm that break cleanly under light pressure. Over-granulation is avoided because excess water solubilises botanical polysaccharides and forms hard, poorly dispersible agglomerates that do not dissolve rapidly in drinking water. The wet granules are transferred to a fluid-bed dryer with an inlet air temperature of 60–80°C and a product temperature of 35–45°C; final moisture is controlled at 2–5% by loss on drying under USP <731>. Dried granules are screened through a 0.8 mm sieve and may be filled into sachets or bulk containers.

Granule performance is evaluated by particle-size distribution, moisture, and dispersibility in water at 20°C. A dispersibility test is conducted by adding a 5 g sample to 500 mL of water and stirring at 50 rpm; visible lumps should be absent within 3 minutes. If granules are intended for in-feed application, flowability is measured under USP <1174> and the granules are blended with the feed carrier using a double-ribbon mixer operated at 15 rpm for 15 minutes. The granule route is preferred when the final feed contains less than 1000 ppm of the active powder because it reduces segregation and improves sampling accuracy at the mill. Long-term storage of granules should be supported by data at 25°C and 60% RH for up to 24 months, with an intermediate condition at 30°C and 65% RH where tropical distribution is anticipated. No stability conclusion is possible without product-specific marker assay data.

In medicated feed premix manufacturing, the API is first diluted in a carrier such as ground corn cob, rice hulls, or calcium carbonate to improve metering accuracy and to prevent segregation during bulk transport. The carrier is screened to 300–850 µm and dried to 8–10% moisture before use. Potency is expressed in grams of active powder per tonne of complete feed; common premix inclusion rates range from 1–5 kg/t depending on the target final dose. A paddle or double-ribbon mixer with a working capacity of 1000 kg is filled to 70–80% of rated volume. Sampling ports are placed at left, centre, and right zones, and at top and bottom depths. The coefficient of variation of the assayed active marker should not exceed 5.0% after the validated mixing time. Equipment cleaning and inspection requirements follow 21 CFR Part 225; mixers used for medicated feeds must be constructed to permit cleanout and visual inspection of contact surfaces.

Stability in the premix is influenced by contact with mineral trace elements. Copper sulfate and zinc oxide can catalyse oxidative degradation of polyphenolic fractions; if the premix contains 500–1000 ppm copper, the formula is protected with a food-grade antioxidant and packed in polyethylene-lined paper sacks. Storage under 25°C and 60% RH for 6 months is the standard pre-marketing confirmation condition, with accelerated data at 40°C and 75% RH useful for failure-mode identification. The carrier bulk density should be matched to the destination feed to avoid particle-size and density mismatch segregation. A bulk density difference larger than 0.15 g/mL between carrier and complete feed is a known risk factor for ingredient separation during pneumatic transfer. Sampling for potency is performed after the premix has passed through conveying equipment, not only at the mixer discharge.

When the API is distributed below 100 ppm in a free-choice mineral matrix

The low-inclusion oral powder route is used when animals receive the API through a free-choice mineral block, a salt mixture, or a top-dressing powder. The primary technical risk at low inclusion is not the active content but the competition between segregation, dusting, and bulk carrier adhesion. The API is first pre-blended with a small portion of the carrier at a 1:10 ratio before being introduced into the main mixer. A V-blender or double-ribbon mixer is operated at 15–20 rpm for 20–30 minutes. The active powder fraction below 74 µm is maintained between 15–25% to limit dusting while retaining surface adherence. The carrier is selected to have a median particle size of 150–300 µm and a Hausner ratio below 1.25, measured under USP <616>. A Hausner ratio above 1.35 indicates that the powder bed will consolidate unpredictably in transport and is unsuitable for low-level distribution.

Blending uniformity is verified by taking 10 samples with a thief sampler at different heights and angular positions. Each sample is assayed by a qualified HPLC method. The relative standard deviation of the active marker should be ≤5.0% for batch release. If the RSD exceeds 5.0% but remains below 8.0%, the batch may be released only after additional mixing and resampling. Above 8.0%, the batch is reworked because downstream feed mills cannot be relied upon to correct gross non-uniformity. The powder is packed in bags with a moisture barrier layer; the empty-bag residual after discharge should not exceed 0.5 g per 25 kg bag during industrial transfer. Published data for this specific product in free-choice mineral matrices is limited, so the finished manufacturer must establish a product-specific sampling plan rather than relying on generic mixer qualification data.

Oral solution pH, cosolvency and preservative challenge criteria

The oral solution route uses a clarified aqueous extract or a suspended microfine fraction rather than the whole crude powder. For drinking-water applications, the solution is adjusted to pH 3.5–5.5 with citric acid monohydrate to suppress microbial growth and to maintain the solubility of acidic marker fractions. Propylene glycol is added at 5–15% v/v or glycerol at 5–20% v/v as a cosolvency aid. Polysorbate 80 is limited to below 0.5% w/v because higher concentrations can form inverse micelles with lipophilic marker fractions and destabilise the solution during cold storage. Preservative efficacy is tested under USP <51>; the compendial bacterial reduction thresholds are 1.0 log at 7 days, 3.0 log at 14 days, and no increase at 28 days, while yeast and mould counts must show no increase at 7, 14, and 28 days. The finished solution is filtered through a 10 µm polypropylene bag filter to control visible particulates before filling.

Stability is evaluated in both glass bottles and plastic dosing containers. The pH is measured under USP <791>; an observed pH shift of 0.5 units within 90 days at 40°C is treated as an early warning of polysaccharide hydrolysis or organic acid degradation. The product is protected from light because polyphenolic components undergo photo-oxidation in clear containers; amber glass or opaque high-density polyethylene is preferred. A final target shelf-life cannot be fixed without manufacturer-generated bracketing data, but a typical screening matrix includes 25°C and 60% RH for 24 months, 30°C and 65% RH for 12 months, and 40°C and 75% RH for 6 months. Solutions containing botanical extracts should not be combined with strong oxidising agents or stored in metal containers without a verified protective lining, because oxidation can cause colour darkening and loss of marker assay.